Liu Yang, Wang Xiang, Zeng Xingzhi, Wu Yinghua, Liu Xinrong, Tan Juan, Li Xiaoyan
Department of Pathology, The Third Xiangya Hospital of Central South University, Changsha, Hunan, 410013, China.
Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Open Med (Wars). 2022 Jul 6;17(1):1183-1202. doi: 10.1515/med-2022-0510. eCollection 2022.
The function of small ubiquitin-like modifier (SUMO)-related genes in hepatocellular carcinoma (HCC) remains unclear. This study aimed to analyze the expression profile and prognostic relevance of SUMO-related genes using publicly available data. A set of bioinformatics tools and experiments were integrated to explore the mechanism of the genes of interest. The least absolute shrinkage and selection operator Cox regression analysis was used to construct a prognostic model. SUMO-2 and SUMO-activating enzyme subunit 1 (SAE1) were upregulated in HCC. The enrichment analysis indicated that SUMO-2 and SAE1 might regulate the cell cycle. The downregulation of SAE1 inhibited the proliferation of HCC cells, whereas the upregulation of the gene promoted cell proliferation. IGF2BP3 contributed to the upregulation of SAE1 in an N6-methyladenosine (m6A)-dependent way. Eventually, an SAE1-related risk score (SRRS) was developed and validated in HCC. SRRS could serve as an independent prognostic factor and predict the efficiency of transarterial chemoembolization in patients with HCC.
小泛素样修饰物(SUMO)相关基因在肝细胞癌(HCC)中的作用尚不清楚。本研究旨在利用公开可用数据分析SUMO相关基因的表达谱及其与预后的相关性。综合运用了一系列生物信息学工具和实验来探索相关基因的作用机制。采用最小绝对收缩和选择算子Cox回归分析构建预后模型。SUMO-2和SUMO激活酶亚基1(SAE1)在HCC中上调。富集分析表明,SUMO-2和SAE1可能调控细胞周期。SAE1的下调抑制了HCC细胞的增殖,而该基因的上调则促进细胞增殖。IGF2BP3以N6-甲基腺苷(m6A)依赖的方式促成了SAE1的上调。最终,开发了一种SAE1相关风险评分(SRRS)并在HCC中进行了验证。SRRS可作为独立的预后因素,并预测HCC患者经动脉化疗栓塞的疗效。